-+ 0.00%
-+ 0.00%
-+ 0.00%

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

The Motley Fool·11/19/2026 06:20:00
Listen to the news

Key Points

  • Moderna’s personalized melanoma vaccine, paired with Merck’s Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial.

  • Analysts warmed to Moderna’s vaccine after the full data showed a 58% lower risk of recurrence or death after six months.

  • Beyond melanoma, Moderna and Merck are testing the vaccine in other cancers, including early-stage pancreatic cancer, with 55% of patients relapse-free at 17 months.

Moderna (NASDAQ: MRNA) delivered promising results for its experimental cancer vaccine on Oct. 22, yet its stock plunged anyway. But looking past the headlines, there's more to the story than the trial results suggest, and investors may be overlooking the real opportunity.

A scientist working in a lab.

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

A promising cancer vaccine fell short of expectations

At first glance, Moderna delivered the kind of clinical milestone that investors had been waiting for: positive Phase 3 results for its personalized melanoma vaccine, intismeran autogene, developed in partnership with Merck. But despite the solid results, Moderna shares fell more than 25% during the Oct. 22 session.

The sell-off followed an unexpected leak of the trial results ahead of their scheduled presentation at the European Society for Medical Oncology (ESMO) Congress. In the trial, the vaccine, when administered alongside Merck's Keytruda, reduced the risk of cancer recurrence or death by 42% compared with Keytruda alone.

On paper, these were encouraging results, but Moderna stock had already rallied following an earlier Phase 2 study. Indeed, this appears to be the case of the market wanting something even better.

For example, some analysts expected the Phase 3 hazard ratio to come in below 0.60, which would mean the vaccine reduces the risk of recurrence or death by more than 40%. Yet the actual result came in at 0.58, which technically cleared that threshold, but only narrowly.

In the end, given the high expectations, investors viewed the results as a disappointment. But there's more here than the headline numbers suggest.

The full conference presentation painted a more encouraging picture

Several analysts softened their initial views after the full presentation, recognizing that the vaccine delivered a meaningful improvement over Keytruda alone. The vaccine requires a series of personalized immunizations, which reduced the risk of recurrence or death by 58% based on outcomes six months or more after the initial treatment.

On top of that, the safety profile was notable. In fact, serious treatment-related adverse events occurred in around 10% of patients receiving the Moderna-Merck combination, compared with 30% in the separate NADINA trial of Opdivo and Yervoy.

That means Moderna's approach can potentially deliver additional clinical benefits without necessarily requiring patients to tolerate more aggressive immunotherapy combinations. As such, intismeran could still become an attractive option for patients less likely to tolerate dual checkpoint blockade, a cancer treatment that uses two different immunotherapy drugs.

Perhaps more importantly, though, Moderna's opportunity could be much bigger than melanoma.

The bigger opportunity could go beyond melanoma

Intismeran uses personalized mRNA technology to train a patient's immune system to recognize specific mutations associated with their cancer. Unlike conventional vaccines designed to prevent infections, this approach is intended to help the immune system identify and attack cancer cells that may otherwise evade detection.

It's also where the broader opportunity becomes something more: If the technology proves effective across different cancer types, Moderna could develop an entirely new category of personalized cancer treatments.

In fact, Moderna and Merck are already assessing intismeran's potential for other types of cancer, including renal cell carcinoma, bladder cancer, and non-small cell lung cancer. Plus, Moderna presented preliminary data from a study evaluating intismeran alongside chemotherapy in pancreatic cancer, with 55% of patients remaining relapse-free after 17 months of follow-up.

Despite these developments, intismeran still requires FDA approval, and overall survival data remain preliminary. On top of that, its effectiveness in other cancer types has yet to be proven.

Finally, today's valuation is also a concern. Right now, Moderna stock trades at a price-to-sales (P/S) ratio of about 35 times, so investors continue to have high expectations around future growth. Meanwhile, Merck trades at a forward price-to-earnings (P/E) ratio of about 16.

Ultimately, at today's valuation, the market may be focusing too much on one trial result and not on Moderna's longer-term business.

Why Moderna still deserves a closer look

Overall, Moderna's cancer vaccine may not have met Wall Street analysts' expectations, but it's still a meaningful clinical achievement. Looking ahead, investors need to be patient as the vaccine moves toward commercialization, but dismissing Moderna based on one trial result could mean overlooking a much bigger opportunity.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.